NCT00446446 2022-10-05
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Amgen
Phase 2 Completed
Amgen
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Amgen
University of Pittsburgh
Amgen
UNC Lineberger Comprehensive Cancer Center